Ukrainian Pharma: challenges and opportunities Pharmaceutical Industry Review, special issue, December 2022
INFORMATION ON THE COMPANY
ACINO, a Swiss pharmaceutical company with headquarters in Zurich, focuses its activities on target markets in the Middle East, Africa, CIS and Latin America. We offer high-quality medicines to assure access to affordable healthcare in emerging markets. Being an international partner to many pharmaceutical companies ACINO provides ready solutions starting from medicines R&D and registration to contract manufacturing, packaging and logistics. ACINO started operations in Ukraine in 2015, its activities are focused mostly on R&D and manufacturing of highly technological generic drugs with additional properties. In Ukraine ACINO’s headquarters are situated in Kyiv as well as perform functions of the company’s business regional headquarters in the CIS region. PHARMA START, ACINO’s cutting-edge manufacturing plant in Kyiv, is certified in compliance with GMP EU standards. It is equipped with scientific-research laboratory for R&D of generic drugs. Our product portfolio – medicinal drugs, dietary supplements, and medical devices – is including over 80 products for application in neurology, psychiatry, cardiology, general therapy, and endocrinology. ACINO team in Ukraine consists of 840 highly qualified specialists.
ACINO: quality you may rely on
Since the first day of russia’s military invasion the company ACINO in Ukraine is persistently working in 24/7 mode to support the national pharmaceutical industry, in particular: • Production of high-quality medicines on its own PHARMA START manufacturing plant;
• Regular supply of critically important vital medicines from reliable international partners to the territory of Ukraine;
• Regular supply of essential medicines to distributors and pharmacy chains;
• Provision of humanitarian and material aid
Manufacturing plant operations ACINO pharmaceutical plant has full-cycle production operations, ensuring uninterrupted access to necessary medicines for Ukrainian citizens.
58 BACK TO CONTENTS
Regularly, the company is investing in the modernization of production facilities and the development of scientific- research activities to expand opportunities to develop
www.promoboz.com
www.promoboz.com |
www.cphem.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
